Table 3.
Clinical Efficacies Of EGFR-TKIs For SqCLC Patients With EGFR Mutations
Author | Total Cases | ORR | DCR | mPFS (Months) | mOS (Months) |
---|---|---|---|---|---|
Amit Joshi et al20 | 19 | 26.3% | 47.3% | 5 | 6.6 |
Cho et al18 | 12 | 50% | 75% | 3.67 | 30.23 |
Liu et al31 | 44 | 43.2% | 77.3% | 5.1 | 17.2 |
Xu et al32 | 26 | 30.8% | 73.1% | 3.98 | NA |
Our study | 24 | 28.6% | 78.6% | 4.7 | 10.6 |
Abbreviations: ORR, overall response rate; DCR, disease control rate; mPFS, median progression-free survival; mOS, median overall survival.